Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Examination of the Efficacy, Safety, and Gender Differences in Using Varenicline as an Aid to Smoking Cessation in a Population of Methadone Maintained Opioid Dependent Patients (Pilot Trial)
Brief Summary: The main hypotheses guiding the study are:

1. Stable methadone maintenance patients receiving varenicline will be more likely to maintain abstinence than patients receiving placebo
2. There will be no differences in the type and number of symptoms reported between stable methadone maintenance patients receiving varenicline and placebo
3. There will be no changes in methadone dosage between abstinent and non-abstinent smokers
4. There will be no differences in efficacy, withdrawal symptoms, and safety of varenicline between male and female participants


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
B: Arm Label: Varenicline treatment as usual (TAU); Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Varenicline directly observed therapy; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline directly observed therapy, Varenicline treatment as usual (TAU)
C: Arm Label: ABDC; Type: EXPERIMENTAL; Interventions: Other: Myblu variant A, Other: Myblu variant B, Other: Myblu variant C, Other: Myblu variant D | Arm Label: BCAD; Type: EXPERIMENTAL; Interventions: Other: Myblu variant A, Other: Myblu variant B, Other: Myblu variant C, Other: Myblu variant D | Arm Label: CDBA; Type: EXPERIMENTAL; Interventions: Other: Myblu variant A, Other: Myblu variant B, Other: Myblu variant C, Other: Myblu variant D | Arm Label: DACB; Type: EXPERIMENTAL; Interventions: Other: Myblu variant A, Other: Myblu variant B, Other: Myblu variant C, Other: Myblu variant D | Arm Label: EFHG; Type: EXPERIMENTAL; Interventions: Other: Myblu variant E, Other: Myblu variant F, Other: Myblu variant G, Other: Myblu variant H | Arm Label: FGEH; Type: EXPERIMENTAL; Interventions: Other: Myblu variant E, Other: Myblu variant F, Other: Myblu variant G, Other: Myblu variant H | Arm Label: GHFE; Type: EXPERIMENTAL; Interventions: Other: Myblu variant E, Other: Myblu variant F, Other: Myblu variant G, Other: Myblu variant H | Arm Label: HEGF; Type: EXPERIMENTAL; Interventions: Other: Myblu variant E, Other: Myblu variant F, Other: Myblu variant G, Other: Myblu variant H | Intervention Type: OTHER; Name: Myblu variant A; Assigned to Arm(s): ABDC, BCAD, CDBA, DACB | Intervention Type: OTHER; Name: Myblu variant B; Assigned to Arm(s): ABDC, BCAD, CDBA, DACB | Intervention Type: OTHER; Name: Myblu variant C; Assigned to Arm(s): ABDC, BCAD, CDBA, DACB | Intervention Type: OTHER; Name: Myblu variant D; Assigned to Arm(s): ABDC, BCAD, CDBA, DACB | Intervention Type: OTHER; Name: Myblu variant E; Assigned to Arm(s): EFHG, FGEH, GHFE, HEGF | Intervention Type: OTHER; Name: Myblu variant F; Assigned to Arm(s): EFHG, FGEH, GHFE, HEGF | Intervention Type: OTHER; Name: Myblu variant G; Assigned to Arm(s): EFHG, FGEH, GHFE, HEGF | Intervention Type: OTHER; Name: Myblu variant H; Assigned to Arm(s): EFHG, FGEH, GHFE, HEGF
D: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A